Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU) today announced two late-breaking poster presentations supporting its Inherent Health® Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 – April 1, 2015, in Boston.
“Data from these two important studies continue to enhance our understanding of the influence of genetics on both body composition and weight loss in response to particular diet and exercise programs,” stated Dr. Lynn Doucette-Stamm, PhD, Vice-President of Development and Clinical Operations of Interleukin. “Improvements in body composition, particularly reductions in body fat percentage, is a key goal in any weight loss program. Healthcare professionals and individuals are looking for effective ways to achieve more meaningful weight loss, and these data support the use of Interleukin’s Weight Management Genetic Test in guiding diet and exercise programs that will improve body composition and the ultimate goal of lasting, more meaningful weight loss.”
The posters, titled “Influence of Metabolic Genotyping on Weight Loss and Body Composition in Women Participating in a 6 Month Diet and Exercise Program; Preliminary Findings” and “Influence of Obesity-Related Genotype on Weight Loss Success and Body Composition Changes While Participating in a 3-Month Exercise and Weight Loss Program; Preliminary Findings,” are being presented by the researcher from the Exercise and Sports Nutrition Lab, Texas A&M University, during the Late-Breaking Program:
Date and Time: April 1, 2015, 10:00 a.m. to 11:00 a.m. (ET)
Location: Hall B
Abstract Number: LB240 and LB241
Session: Nutrition: ASN Variability in Response to Diet and Food
A copy of the poster presentations can be found here: http://ilgenetics.com/wp-content/uploads/2015/03/BSanchez_FASEB_2015.pdf and http://ilgenetics.com/wp-content/uploads/2015/03/Coletta_FASEB_2015.pdf
These studies provide preliminary findings suggesting that genetic variations may influence the response to macronutrients in the diet, and that individuals participating in a diet and exercise program may experience improvements in body composition and weight loss when the diet type is aligned with the genetic profile.
About Interleukin’s Weight Management Genetic Test
Sold under the Inherent Health® brand, Interleukin’s Weight Management Genetic Test offers a genetics-based program that will determine whether an individual is likely to benefit more from a low fat, low carbohydrate or balanced calorie reduced diet, and whether an individual is likely to obtain greater benefit from normal or more vigorous exercise for the most efficient weight loss. The test provides new information, beyond traditional means, to help an individual understand and utilize the genetic factors that influence weight gain.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements, including statements that the Company intends to enhance its internal marketing capabilities by leveraging partnering programs, the Company will establish additional collaborations with pharmaceutical companies, that the Company believes that cash and cash equivalents as of December 31, 2014 is sufficient to fund the Company’s operations for at least the next twelve months, and that the net proceeds from the private placement and loan will be used primarily to accelerate commercialization of the Company’s proprietary genetic tests and for general corporate and working capital purposes . Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.